Skip to main content

Oxurion AG

Leuven, To belgicBoston, MA, USAMarch 17, 2022 – 07.00 PM CET Oxurion AG (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next-generation, off-the-shelf ophthalmic therapies, with clinical-stage assets in retinal vascular disorders, announced today that, in accordance with Belgian transparency legislation1it had received two transparency notifications following the closing of its private placement announced on March 7, 2022.

Oxurion received a transparency notice dated March 14, 2022 from Fidelity Management & Research Company LLC, stating that pursuant to a stock acquisition on March 7, 2022, through the private placement, it had acquired 3,128,819 ordinary shares, which represents 6.7% of the voting rights of Oxurion, and thus crosses the threshold of 5% (the “Loyalty Notification”).

Oxurion also received a Transparency Notification dated March 15, 2022 from Novartis Pharma AG and Novartis AG, which confirmed Novartis Pharma AG’s ownership of 2,177,226 ordinary shares, which following the private placement now represents 4, 7% of the voting rights of Oxurion, and thus also crossed the 5% threshold (downward) (the “Novartis Notification”).

Content of the Loyalty notification
Reason for notifications
Acquisition or disposal of securities with voting rights or voting rights.

Notifications by
A parent company or a controlling person.

Persons subject to the notification obligation

Date on which the threshold East crossed
March 7, 2022

Threshold crossed
5%

Denominator
46,628,892

Details notified
See Appendix 1.

Chain of controlled companies through which the interest is actually held
Fidelity Management & Research Company LLC is controlled by FMR LLC. FMR LLC is not a controlled entity.

Content of the Novartis Notification
Reason for notifications
Passive crossing of a threshold.

Notifications by
A parent company or a controlling person.

Persons subject to the notification obligation

Date on which the threshold East crossed
March 7, 2022

Threshold crossed
5%

Denominator
46,628,892

Details notified
See Appendix 2.

Chain of controlled companies through which the interest is actually held
Novartis Pharma AG is a 100% direct subsidiary of Novartis AG.

On Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next-generation ophthalmic therapies designed to better preserve vision in patients with retinal vascular disorders, including diabetic macular edema (DME), the leading cause of vision loss. in diabetic patients. worldwide as well as other conditions including wet age-related macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion aims to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapies. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the 40-50% of DME patients with a suboptimal response to anti-VEGF treatment. THR-687 is a highly selective pan-RGD integrin antagonist that is being developed as a potential first-line treatment for patients with DME as well as wet AMD and potentially ME-RVO. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For more information please contact:

ANNEX 1

APPENDIX 2

1 Article 14, first paragraph, of the law of 2 May 2007 relating to the disclosure of major shareholdings.

Attachment